Merck & Co., Inc. (MRK) News
Track canonical SquawkNews coverage tagged to MRK, Merck & Co., Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 121 indexed stories across 44 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MRK - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
MRK - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
NEWS | Sep 18, 2026, 11:03 AM UTC
M
Merck gets positive EU CHMP opinion for KEYTRUDA plus Padcev in bladder cancer
Merck said the EU CHMP adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) as perioperative treatment for adults with resectable muscle-invasive bladder cancer.
REGULATION | Sep 18, 2026, 10:55 AM UTC
L
MRK - Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
MRK - Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
NEWS | Sep 18, 2026, 10:48 AM UTC
H
Novo and Orbis sign up to $1.4B deal for oral therapies
Orbis Medicines signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases traditionally treated with injectable drugs.
MNA | Sep 17, 2026, 11:00 AM UTC
M
AstraZeneca shares jump after J.P. Morgan reiterates Overweight
AZN rose about 2.16% intraday after J.P. Morgan reiterated an Overweight rating, citing six Phase III readouts due in 2027 with more than $10 billion in risk-adjusted peak sales.
EQUITY | Sep 16, 2026, 07:11 PM UTC
L
MRK: Pipeline advances and strategic deals drive growth, with new assets and AI boosting future potential
Transformation is progressing with strong product launches, positive clinical data, and business development driving growth. Pipeline assets like INT and sac-TMT offer significant upside, while LIPFENDRA is positioned fo
NEWS | Sep 14, 2026, 09:03 PM UTC
H
MRK: Strong pipeline, policy momentum, and innovation signal significant growth ahead
Transformation is progressing with strong product launches, positive data, and a robust pipeline, including new assets not yet in long-term guidance. Policy advocacy focuses on access and affordability, while AI and busi
NEWS | Sep 14, 2026, 08:26 PM UTC
L
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Summit Therapeutics NASDAQ:SMMT on Sunday said ivonescimab significantly extended survival compared with Merck’s NYSE:MRK Keytruda in a late-stage lung cancer trial conducted by its partner Akeso OTC:AKESF in China.Ivone
GEOPOLITICS | Sep 13, 2026, 05:23 PM UTC
L
HSBC raises Merck price target to $172 from $150
Benzinga/TradingView reports HSBC kept Merck at Buy and raised its price target to $172.00 from $150.00.
EQUITY | Sep 10, 2026, 01:52 PM UTC
H
MRK reports portfolio transformation and pipeline advances
EARNINGS | Sep 09, 2026, 08:27 PM UTC
L
MRK highlights pipeline strength and diversification strategy
Management cited a robust pipeline with increased revenue projections, diversification efforts, and disciplined investment in new launches. Oncology progress in sac-TMT and INT was highlighted, alongside new products in
EQUITY | Sep 09, 2026, 07:23 PM UTC
L
25 dividend stocks to watch as market sentiment turns negative
Dividend-paying stocks gained renewed momentum Wednesday as investors shifted toward safety amid a slide in broader market averages.The blue-chip Dow Jones Industrial Average TVC:DJI dropped to a new one-month low while
ENERGY | Sep 09, 2026, 04:51 PM UTC
L
PostEra’s two fertility programs acquired by MRK unit
MRK unit is acquiring PostEra’s two fertility programs.
EQUITY | Sep 09, 2026, 04:44 PM UTC
L
Merck price target raised to $161 from $127 by Leerink
Leerink Partners raised its Merck price target to $161.00 per share from $127.00, according to TradingView News.
EQUITY | Sep 09, 2026, 04:13 PM UTC
L
Merck price target raised to $170 by Guggenheim
Guggenheim raised its Merck price target to $170.00 from $146.00 and maintained a Buy rating.
EQUITY | Sep 08, 2026, 01:48 PM UTC
L
Merck to participate in Morgan Stanley Global Healthcare conference fireside chat
Merck says Robert M. Davis and Dr. Dean Y. Li are scheduled for a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 08, 2026, 10:45 AM UTC
L
Wells Fargo raises Merck price target to $170 from $150
Wells Fargo raised its Merck price target to $170.00 per share from $150.00 and maintained its Overweight rating, per TradingView News / Benzinga ratings actions.
EQUITY | Sep 04, 2026, 02:37 PM UTC
L
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels - Heard on the Street — WSJ
By David WainerThe excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies. But it is also creating a gold rush in a gro
COMMODITIES | Sep 04, 2026, 09:30 AM UTC
M
Merck’s Keytruda faces 2028 biosimilar rights warning
Merck priced at $151.07 received a warning as Cipla’s U.S. subsidiary secured exclusive U.S. commercialization rights for Qilu Pharmaceutical’s proposed pembrolizumab biosimilar QL21.
EQUITY | Sep 03, 2026, 09:36 PM UTC
M
Summit Therapeutics stock jumps as ivonescimab extends survival in China
Shares of Summit Therapeutics rose more than 12% Thursday morning after the company said ivonescimab is extending survival in a Chinese lung cancer study, lifting the stock to $16.46.
EQUITY | Sep 03, 2026, 04:00 PM UTC
M
Cipla partners with Qilu to license Keytruda biosimilar for U.S.
India’s Cipla said its U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s Keytruda for the U.S. market.
GEOPOLITICS | Sep 03, 2026, 03:23 PM UTC
M
Novartis signs deal worth up to $3.22B with Alteogen tech
Alteogen (KRX:196170) said it signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous drugs.
EQUITY | Sep 02, 2026, 12:10 PM UTC
L
Merck executives scheduled for Wells Fargo 21st Healthcare Conference
Merck (MRK) said Caroline Litchfield, EVP and CFO, and Dr. Dean Y. Li, EVP and president of Merck Research Laboratories, are scheduled to participate in a fireside discussion at the Wells Fargo 21st Annual Healthcare Con
EQUITY | Sep 02, 2026, 10:45 AM UTC
L
Pharma Industry Stares Down Biggest Patent Cliff in Decades — WSJ
Pharma Industry Stares Down Biggest Patent Cliff in Decades — WSJ
EQUITY | Aug 29, 2026, 01:09 AM UTC
L
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
EQUITY | Aug 28, 2026, 10:00 AM UTC
H
Indexes end close to flat after hot inflation data ahead of Nvidia earnings
Indexes end close to flat after hot inflation data ahead of Nvidia earnings
MACRO | Aug 26, 2026, 08:01 PM UTC
H
Wall Street dips on hot inflation data ahead of Nvidia earnings
Wall Street dips on hot inflation data ahead of Nvidia earnings
MACRO | Aug 26, 2026, 06:23 PM UTC
H
Wall St awaits Nvidia's AI verdict after hot inflation data
Wall St awaits Nvidia's AI verdict after hot inflation data
MACRO | Aug 26, 2026, 04:25 PM UTC
M
Dow Jones opens 0.20% higher as Nvidia leads gains
The Dow Jones Index is up 108 points, or 0.20%, on Tuesday, led by Nvidia (1.65%), Cisco Systems (1.64%) and Merck (1.25%).
EQUITY | Aug 25, 2026, 01:40 PM UTC
L
Dow Jones opens 0.14% higher as Visa leads gainers
The Dow Jones Index is up 76 points, or 0.14%, on Monday, with Visa, UnitedHealth and Walt Disney among the top gainers and Caterpillar, Boeing and Merck among the biggest losers.
EQUITY | Aug 24, 2026, 01:40 PM UTC
L
Dow Jones closes 1.05% higher as Goldman, Merck lead gains
The Dow Jones Index gained 555 points, or 1.05%, on Friday to close at 53,315, with Goldman Sachs, Merck and Salesforce leading the advance.
EQUITY | Aug 21, 2026, 08:35 PM UTC
H
Iovance Biotherapeutics trades at 52-week high after sector-linked momentum
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is trading at a 52-week high despite no company-specific news, while the post also cites second-quarter results and reaffirmed fiscal 2026 sales guidance.
EARNINGS | Aug 20, 2026, 05:14 PM UTC
M
Merck and Moderna report interim Phase 3 vaccine data hits endpoint
Merck and Moderna said interim Phase 3 data for Moderna’s personalized cancer vaccine met its primary endpoint, with Wells noting potential beneficiaries include RGEN, DHR, TMO and MRVI.
EQUITY | Aug 20, 2026, 01:25 PM UTC
L
Merck gets dueling analyst calls after vaccine data rally
Merck draws mixed analyst action after promising cancer vaccine results lifted shares almost 13% yesterday, with RBC Capital Markets downgrading to hold and Morgan Stanley upgrading to buy.
EQUITY | Aug 20, 2026, 01:14 PM UTC
M
Merck target raised to $160 after Moderna cancer therapy data
Goldman Sachs raises its price target on Merck to $160 from $140 after partner mRNA cancer therapy data involving Moderna.
EQUITY | Aug 20, 2026, 12:55 PM UTC
L
Tempus AI gains as BTIG lifts price target, cancer trial readthrough in focus
Tempus AI Inc. shares are trading higher Thursday after BTIG maintained a Buy rating and raised its price forecast to $80, while investors also focus on a Phase 3 cancer trial readthrough tied to the pending Personalis a
EQUITY | Aug 20, 2026, 12:35 PM UTC
L
RBC downgrades Merck to Sector Perform, raises target to $150
RBC Capital downgrades Merck (MRK) to Sector Perform from Outperform and lifts its price target to $150 from $142.
EQUITY | Aug 20, 2026, 11:56 AM UTC
M
UBS downgrades Merck to Neutral, cuts price target to $150
UBS downgrades MRK to Neutral from Buy and sets a $150.00 price target.
EQUITY | Aug 20, 2026, 11:56 AM UTC
L
MRK Positive updates further contribute to improving sentiment for MRK shares @ BMO
MRK Positive updates further contribute to improving sentiment for MRK shares @ BMO
EQUITY | Aug 20, 2026, 11:51 AM UTC
M
UBS downgrades Merck to Neutral from Buy
UBS downgrades MRK to Neutral from Buy, changing its view on the stock; no catalyst was supplied in the alert.
EQUITY | Aug 20, 2026, 11:48 AM UTC
H
Analysts issue multiple rating downgrades across several stocks
Analysts cut ratings on ALL to Underperform at Keefe, COTY to Sector Perform at RBC, MRK to Sector Perform at RBC and UBS, TJX to Neutral at Citi, and WHD to Neutral at Citi.
EQUITY | Aug 20, 2026, 11:25 AM UTC
L
MRK MRNA raising PTs — whats priced in, whats next? @ UBS
MRK MRNA raising PTs — whats priced in, whats next? @ UBS
EQUITY | Aug 20, 2026, 11:09 AM UTC
L
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
EQUITY | Aug 20, 2026, 11:04 AM UTC
L
MRK upgraded to Overweight, $179 price target at MSCO
MSCO upgraded MRK from Equal Weight to Overweight and set a $179 price target, up from $116, per Hammerstone MarketTalk.
EQUITY | Aug 20, 2026, 11:03 AM UTC
M
RBC downgrades Merck to Sector Perform; raises PT to $150
RBC Capital downgrades Merck to Sector Perform from Outperform and raises its price target to $150 from $142, per TradeXchange Newsdesk.
EQUITY | Aug 20, 2026, 10:33 AM UTC
H
U.S. stock futures fall after Trump launches Iran economic offensive
U.S. stock futures are lower as President Donald Trump announces “Operation Economic Fury” against Iran, lifting geopolitical tensions and pushing Brent crude higher.
EARNINGS | Aug 20, 2026, 09:24 AM UTC
M
Merck upgraded to Overweight at Morgan Stanley, target raised to $179
Merck (MRK) is upgraded to Overweight from Equal Weight at Morgan Stanley, which also raises its price target to $179 from $116.
EQUITY | Aug 19, 2026, 09:22 PM UTC
M
Dow Jones closes 0.17% higher as Merck, Salesforce lead
The Dow Jones Index rose 89 points, or 0.17%, on Wednesday to close at 53,433, with Merck, Salesforce and Amgen leading gains and Caterpillar, Goldman Sachs and Honeywell International lagging.
EQUITY | Aug 19, 2026, 08:35 PM UTC
L
Morgan Stanley upgrades Merck to Overweight, raises target to $179
Morgan Stanley upgrades Merck to Overweight from Equalweight and lifts its price target on Merck to $179 from $116.
EQUITY | Aug 19, 2026, 08:33 PM UTC
L
MRK upgraded to Overweight; price target raised to $179
Hammerstone MarketTalk upgrades MRK to Overweight and lifts its $179 price target from $116, while EW is listed as the prior designation.
EQUITY | Aug 19, 2026, 08:24 PM UTC
L
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub-areas which have all rallied behind the MRNA/MRK news today
EQUITY | Aug 19, 2026, 07:34 PM UTC
M
MRK hits new highs, gains +12.5%
MRK is reported to hit new highs and rise by +12.5%, according to Hammerstone MarketTalk, with no further details or catalyst provided.
EQUITY | Aug 19, 2026, 06:24 PM UTC
H
Treasury buybacks drag yields lower; gold, miners rally
The Treasury’s decision to at least double long-dated debt buybacks pushed benchmark yields lower, weakened the dollar to its lowest since late May and lifted gold-related assets.
EARNINGS | Aug 19, 2026, 05:10 PM UTC
H
Moderna, Merck cancer vaccine hits key Phase 3 endpoints
Moderna and Merck say their personalized mRNA cancer vaccine intismeran with Keytruda met key endpoints in a Phase 3 melanoma trial, cutting recurrence and distant metastasis versus Keytruda alone.
CENTRAL_BANK | Aug 19, 2026, 05:09 PM UTC
L
Leerink says cancer vaccine win should sustain Merck momentum into fall
Leerink says a cancer vaccine win should sustain Merck momentum into fall, with the note referencing MRNA, BNTX and MRK and supplying no further catalyst details.
EQUITY | Aug 19, 2026, 02:39 PM UTC
M
Merck & Co notches best intraday gain since 2009
Merck & Co notches its best intraday gain since 2009, with shares up over 12%, according to the raw alert; no catalyst was supplied.
EQUITY | Aug 19, 2026, 02:14 PM UTC
L
XLV hits new highs after MRK, MRNA lift healthcare
XLV Healthcare rises 1.9% to a new all-time high at $172.80 after MRK and MRNA boost the industry.
EQUITY | Aug 19, 2026, 01:31 PM UTC
H
Merck shares hit 54-year high at $147.00
Merck shares rise to $147.00, the highest level since May 1972, after gaining 8.66% over the past 4 weeks and 59.15% over the last 12 months.
EQUITY | Aug 19, 2026, 01:30 PM UTC
H
Moderna surges after late-stage melanoma vaccine results
Moderna (MRNA) is up more than 90% this morning following an experimental cancer vaccine jointly developed with Merck that showed promise in a late-stage melanoma trial.
EQUITY | Aug 19, 2026, 01:13 PM UTC
L
Tempus rises premarket on Merck, Moderna collaboration news
Tempus shares are up 13% premarket after market talk pointed to expanded strategic collaboration with Merck and an ongoing expanded partnership with Moderna through Tempus AI data platforms.
MNA | Aug 19, 2026, 01:03 PM UTC